Alflutinib methanesulfonate
CAS No. 2130958-55-1
Alflutinib methanesulfonate ( AST2818;AST-2818;ASK120067 )
Catalog No. M13393 CAS No. 2130958-55-1
Alflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 149 | In Stock |
|
10MG | 222 | In Stock |
|
25MG | 374 | In Stock |
|
50MG | 555 | In Stock |
|
100MG | 790 | In Stock |
|
500MG | 1611 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAlflutinib methanesulfonate
-
NoteResearch use only, not for human use.
-
Brief DescriptionAlflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.
-
DescriptionAlflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.Lung Cancer Phase 1 Clinical
-
SynonymsAST2818;AST-2818;ASK120067
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number2130958-55-1
-
Formula Weight664.71
-
Molecular FormulaC29H35F3N8O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO : 5 mg/mL 7.52 mM
-
SMILESCN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)c3cn(C)c4ccccc34)cc1NC(=O)C=C.CS(=O)(=O)O
-
Chemical NameN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide methanesulfonate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. PCT Int. Appl. (2017), WO 2017152707 A1 20170914.
2. PCT Int. Appl. (2017), WO 2017152706 A1 20170914.
2. PCT Int. Appl. (2017), WO 2017152706 A1 20170914.
molnova catalog
related products
-
Peiminine
Peiminine is an effective inhibitor for lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury.
-
EGF816 mesylate
EGF816 (Nazartinib) is a potent, irreversible, mutant-selective EGFR inhibitor with Ki and Kinact of 31 nM and 0.222 min-1, respectively.
-
CCF642
CCF642 is a novel PDI-inhibiting compound with antimyeloma activity.